Track Niagen Bioscience Inc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Niagen Bioscience Inc NAGE · Stock Open Niagen Bioscience Inc in new tab

3.53 USD
P/E
16.19
EPS
0.21
P/B
3.29
ROE
27.07
Beta
2.08
Target Price
12.42 USD
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
P/E16.19
EPS0.21
Book Value1.03
Price to Book3.29
Debt/Equity3.13
% Insiders29.264%
Growth
Revenue Growth0.03%
Earnings Growth0.17%
Estimates
Forward P/E11.72
Forward EPS0.29
Target Mean Price12.42

DCF Valuation

Tweak assumptions to recompute fair value for Niagen Bioscience Inc (NAGE)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Niagen Bioscience Inc Logo Niagen Bioscience Inc Analysis (NAGE)

Is Niagen Bioscience Inc a good investment? Niagen Bioscience Inc (NAGE) is currently trading at 3.53 USD. Market analysts have a consensus price target of 12.42 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 16.19. This valuation is generally in line with the broader market.

Earnings Schedule: Niagen Bioscience Inc is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is 0.29.

Investor FAQ

Does Niagen Bioscience Inc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Niagen Bioscience Inc?

Niagen Bioscience Inc is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 0.21.

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 13, 2016 0.333333
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion